COGT (Cogent Biosciences) Research & Development: $282.12 Mil (TTM As of Mar. 2026)


COGT Cogent Biosciences Inc COGT
25 GF Score
Price $37.53
! 3 Warning Signs
View Full Analysis

What is Cogent Biosciences Research & Development?

Cogent Biosciences COGT +3.36% 25 Research & Development is $282.12 Mil as of Mar. 2026. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cogent Biosciences's Research & Development for the three months ended in Mar. 2026 was $75.37 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $282.12 Mil.

Cogent Biosciences  (NAS:COGT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cogent Biosciences Research & Development Related Terms

Cogent Biosciences Research & Development Historical Data

* Premium members only.

The historical data trend for Cogent Biosciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogent Biosciences Research & Development Chart

Cogent Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.91 121.63 173.76 232.66 269.78

Cogent Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.03 62.20 68.99 75.56 75.37
COGT
25GF Score
Cogent Biosciences Inc COGT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogent Biosciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $282.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $282.12 Mil mean?
Cogent Biosciences (COGT) has a Research & Development of $282.12 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Cogent Biosciences and its competitors.
Is Cogent Biosciences' Research & Development too high?
Cogent Biosciences' current Research & Development is $282.12 Mil. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Research & Development compare to SRRK and RYTM?
Cogent Biosciences' Research & Development of $282.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cogent Biosciences and its competitors. Cogent Biosciences's current Research & Development is $282.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Research & Development of $282.12 Mil. The current Research & Development is $282.12 Mil. Cogent Biosciences' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Research & Development is $282.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cogent Biosciences Business Description

Address 275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score

Get the complete analysis for COGT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.53
Price